Michael Marinaro, President of Medtronic plc, filed a Form 4 on November 4, 2026, disclosing equity awards granted on November 2, 2026, including restricted stock units, performance share units, and stock options.

Key Highlights

  • RSU grant: Marinaro acquired 6,547 restricted stock units at $0 cost, vesting 100% on August 3, 2029.
  • PSU grant: 16,367 performance share units were acquired, with performance conditions to be satisfied on April 27, 2029; payout ranges from 0 to 39,281 shares depending on performance metrics.
  • Stock option grant: 42,994 stock options were acquired at an exercise price of $99.29, expiring November 2, 2036, and becoming exercisable at 25% per year beginning August 3, 2027.
  • Post-transaction ownership: Marinaro beneficially owns 113,353 ordinary shares directly following the reported transactions.
  • Dividend reinvestment: The filing notes that 890 of the shares in the total beneficial ownership figure were acquired through dividend reinvestment since the last report.

Marinaro Receives Multi-Component Equity Award Package at Medtronic

According to the filing, Michael Marinaro, identified as President of Medtronic plc (NYSE:MDT), received three separate equity awards on November 2, 2026. The first is a grant of 6,547 restricted stock units (RSUs), acquired at a price of $0, which the filing states will vest 100% on August 3, 2029. Following this transaction, Marinaro's direct beneficial ownership of ordinary shares stands at 113,353, a figure that the filing notes includes 890 shares acquired through dividend reinvestment since his last report.

The second award consists of 16,367 performance share units (PSUs), also acquired at $0. The filing describes each PSU as "a contingent right to receive one share of Medtronic common stock," with performance conditions set to be satisfied on April 27, 2029. The actual number of shares issued will depend on the level of certain performance metrics achieved over a three-year performance period. The filing states that if target metrics are achieved, 16,367 shares will be issued; if maximum metrics are achieved, 39,281 shares will be issued; and if minimum metrics are not met, the PSUs may vest at 0 shares.

The third component is a grant of 42,994 stock options with a right-to-buy exercise price of $99.29 per share, expiring on November 2, 2036. According to the filing, these options become exercisable at a rate of 25% of the shares granted per year, beginning August 3, 2027. All three awards are held directly by Marinaro. The Form 4 was signed by Patricia Walesiewicz as attorney-in-fact on November 4, 2026.

What Was Disclosed

Medtronic President Michael Marinaro disclosed the receipt of 6,547 RSUs, 16,367 PSUs, and 42,994 stock options on November 2, 2026, all at $0 cost. His direct beneficial ownership of ordinary shares following the transactions is reported as 113,353.